NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa Boerse Stuttgart, saham Neurometrix didagangkan di bawah simbol NLZD.STU.
Berapa ramai pekerja yang dimiliki oleh Neurometrix?▼
Sehingga September 04, 2026, syarikat mempunyai 13 pekerja.
Neurometrix terletak dalam sektor apa?▼
Neurometrix beroperasi dalam sektor Kesihatan & Kesejahteraan.
Bilakah Neurometrix menyiapkan split saham?▼
Pecahan saham terakhir bagi Neurometrix berlaku pada November 20, 2019 dengan nisbah 1:10.
Di manakah ibu pejabat Neurometrix?▼
Ibu pejabat Neurometrix terletak di Woburn, Amerika Syarikat.